Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Interventional × 177Lu-octreotate × Clear all

Phase

Status

Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 99 Cisplatin 96 Radiotherapy 94 pembrolizumab 88 Paclitaxel 73 Carboplatin 70 Nivolumab 67 Gemcitabine 67 Fluorouracil 63 Magnetic Resonance Spectroscopy 62 Dexamethasone 57 Bevacizumab 56 Radiosurgery 52 Docetaxel 51 Rituximab 48 Oxaliplatin 47 Leucovorin 47 fludarabine 44 Capecitabine 44 Biopsy 39 Doxorubicin 37 Etoposide 34 Cytarabine 34 durvalumab 33 Radiation 33 fludarabine phosphate 32 Lenalidomide 32 Drug Therapy 32 Pemetrexed 31 Irinotecan 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡